| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 3, 2008
From the Institute of Biomedical Sciences (J.-S.W., W.-M.C., Y.-T.C., W.-H.F., H.-D.T., Y.-C.C., S.-K.S., J.-J.C., T.-N.L.), Academia Sinica, Taipei, Taiwan; Graduate Institute of Life Sciences (J.-S.W.), National Defense Medical Center, Taipei, Taiwan; Graduate Institute of Clinical Medicine (Y.-S.T.), National Cheng Kung University Medical College, Tainan, Taiwan; National Health Research Institutes (J.-Y.L., K.K.W.), Zhunan, Taiwan; Cardiovascular Center (Y.E.C.), University of Michigan Medical Center, Ann Arbor, Mich; Department of Pathology and Laboratory Medicine (N.M.), University of North Carolina, Chapel Hill, NC; and University of Texas Health Science Center (K.K.W.), Houston, Tex. * To whom correspondence should be addressed. E-mail: kkgo{at}nhri.org.tw
or bmltn{at}ibms.sinica.edu.tw.
Background—Thiazolidinediones have been reported to protect against ischemia-reperfusion injury. Their protective actions are considered to be peroxisome proliferator–activated receptor- Methods and Results—We evaluated the effects of rosiglitazone or PPAR- Conclusions—Ligand-activated PPAR-
Accepted on December 22, 2008
Ligand-Activated Peroxisome Proliferator–Activated Receptor-
Jui-Sheng Wu MS,
Protects Against Ischemic Cerebral Infarction and Neuronal Apoptosis by 14-3-3
Upregulation
(PPAR-
)–dependent; however, it is unclear how PPAR-
activation confers resistance to ischemia-reperfusion injury.
overexpression on cerebral infarction in a rat model and investigated the antiapoptotic actions in the N2-A neuroblastoma cell model. Rosiglitazone or PPAR-
overexpression significantly reduced infarct volume. The protective effect was abrogated by PPAR-
small interfering RNA. In mice with knock-in of a PPAR-
dominant-negative mutant, infarct volume was enhanced. Proteomic analysis revealed that brain 14-3-3
was highly upregulated in rats treated with rosiglitazone. Upregulation of 14-3-3
was abrogated by PPAR-
small interfering RNA or antagonist. Promoter analysis and chromatin immunoprecipitation revealed that rosiglitazone induced PPAR-
binding to specific regulatory elements on the 14-3-3
promoter and thereby increased 14-3-3
transcription. 14-3-3
Small interfering RNA abrogated the antiapoptotic actions of rosiglitazone or PPAR-
overexpression, whereas 14-3-3
recombinant proteins rescued brain tissues and N2-A cells from ischemia-induced damage and apoptosis. Elevated 14-3-3
enhanced binding of phosphorylated Bad and protected mitochondrial membrane potential.
confers resistance to neuronal apoptosis and cerebral infarction by driving 14-3-3
transcription. 14-3-3
Upregulation enhances sequestration of phosphorylated Bad and thereby suppresses apoptosis.
Related Article:
Circulation 2009 119: 1067-1068.
This article has been cited by other articles:
![]() |
F.-I Hsieh, W.-C. Lo, H.-J. Lin, Y.-C. Hsieh, L.-M. Lien, C.-H. Bai, H.-P. Tseng, and H.-Y. Chiou Significant Synergistic Effect of Peroxisome Proliferator-Activated Receptor {gamma} C-2821T and Diabetes on the Risk of Ischemic Stroke Diabetes Care, November 1, 2009; 32(11): 2033 - 2035. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |